25 results about "Streptococcus pneumoniae serotype" patented technology

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the invention typically comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using said novel immunogenic compositions.

To provide an improved process related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein, and a prepared serotype 35B polysaccharide-protein conjugate.SOLUTION: A serotype 35B S. pneumoniae polysaccharide-protein conjugate has a molecular weight of 1,000 kDa to 7,000 kDa. The conjugate comprises a lysine consumption of 3 mol / mol protein to 9 mol / mol protein. A process for making the conjugate comprises activation of the polysaccharide, wherein the activation utilizes periodate in a range of 0.01 to 0.1 moles of periodate per mole of polysaccharide repeating unit.SELECTED DRAWING: Figure 1A

The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate), and to the use thereof. The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate). The vaccine formulations of the present invention would typically include at least one glycoconjugate from Streptococcus pneumoniae serotype in a formulation designed to promote resuspension.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

The invention is related to 26-valent immunogenic compositions comprising 26 different S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. The 26-valent immunogenic compositions are useful for providing protection against S. pneumoniae infection and / or pneumococcal diseases caused by S. pneumoniae including pneumococcal pneumoniae, invasive pneumococcal disease and acute otitis media.

Disclosed are a multivalent Streptococcus pneumoniae capsular polysaccharide-protein conjugate composition and a preparation method therefor. The Streptococcus pneumoniae serotype is selected from 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. The composition can effectively stimulate the production of helper T cells in the body, promote the activation of B cells, and result in immune memory, so as to enable the antibody class to switch from IgM to IgG and enhance immunogenicity, thereby enabling the infants under 2 years of age to produce effective immune responses against corresponding diseases.

The application discloses a Streptococcus pneumoniae glycoprotein biological combination vaccine and a preparation method and application thereof. The application provides application of a recombinant plasmid with DNA molecule A and a recombinant plasmid with DNA molecule B in preparation of a Streptococcus pneumoniae vaccine; the DNA molecule A has a CPS synthesis related gene cluster of a Streptococcus pneumoniae K5 serotype; the DNA molecule B has a pglL gene and a fusion gene I; the fusion gene I comprises, from upstream to downstream, an NP gene and a gene coding a glycosylation site. In the application, the Streptococcus pneumoniae K5 serotype CPS is transferred to a carrier protein by means of a PglL system, and the obtained glycoprotein has a Streptococcus pneumoniae vaccine function. The application has important application and popularization values for prevention and control of the Streptococcus pneumoniae and treatment of diseases caused by the Streptococcus pneumoniae.

Among its various embodiments, the disclosure provides improved methods for producing glycoconjugates of carrier protein, including CRM197, and bacterial capsular saccharide, including those isolated from various Streptococcus pneumoniae serotypes.

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), and uses of the novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates). The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to vaccination of human individuals, particularly infants and elderly people, against Streptococcus pneumoniae infection using the novel immunogenic compositions.

To provide an improved multivalent pneumococcal conjugate composition and a vaccine containing the composition.SOLUTION: A multivalent pneumococcal conjugate composition contains 22 to 27 different kinds of pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate includes a protein carrier conjugated into capsular polysaccharide derived from a different serotype of streptococcus pneumoniae, and a streptococcus pneumoniae serotype is selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.SELECTED DRAWING: None

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising such immunogenic compositions and uses thereof. The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not present and / or in. The invention also relates to vaccination of human individuals, especially infants and elderly people, against Streptococcus pneumoniae infection using such novel immunogenic compositions.

The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.

The present invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharides and methods for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, methods for their preparation and immunogenic compositions comprising them.

The present invention relates to new vaccine formulations comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the invention typically comprise at least one glycoconjugate from an S. pneumoniae serotype in a formulation designed to facilitate resuspension. [Figure 1] TIFF2025541706000005.tif58160

The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.

The present invention relates to a novel immunogenic composition containing a conjugated Streptococcus pneumoniae capsular sugar antigen (sugar conjugate), a kit containing the immunogenic composition, and the use of the same. The immunogenic composition of the present invention typically contains at least one sugar conjugate derived from a Streptococcus pneumoniae serotype not found in PREVNAR®, SYNFLORIX®, and / or PREVNAR13®. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using the novel immunogenic composition.

To provide antigens which are able to generate a more robust immune response to Streptococcus pneumoniae serotype 3.SOLUTION: A Streptococcus pneumoniae serotype 3 glycoconjugate is provided which comprises a Streptococcus pneumoniae serotype 3 polysaccharide covalently conjugated to a carrier protein (CP) via a spacer, and has the general formula (VII), where X is CH2(CH2)n', n' being 2, and X' is CH2O(CH2)n", n" being 1.SELECTED DRAWING: Figure 1

The present invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and methods of making the same. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, methods for their preparation and immunogenic compositions and vaccines comprising the same.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. The immunogenic compositions of the present invention generally comprise glycoconjugates of at least one Streptococcus pneumoniae serotype not found in and / or in. The invention also relates to vaccination of human subjects, in particular infants and elderly people, against Streptococcus pneumoniae infection using said novel immunogenic compositions.

The invention discloses a streptococcus pneumoniae protein vaccine. The protein vaccine provided by the invention is selected from a protein derived from Streptococcus pneumoniae from any one of the following (i) to (iii): (i) PBP1A protein and / or a mutant of the PBP1A protein and / or a mutant of the PBP1A protein and / or a mutant of the PBP1A protein and / or a mutant of the PBP1A protein and / or the mutant of the PBP1A protein and / or the mutant of the PBP1A protein; (ii) a combination of a PBP1A protein and / or a mutant thereof with at least one of a PhtE protein and / or a mutant thereof, a CbpA protein and / or a mutant thereof, a PspA protein and / or a mutant thereof, and an RrgA protein and / or a mutant thereof; (iii) a first fusion protein and / or a mutant thereof, a second fusion protein and / or a mutant thereof, a PhtE protein and / or a mutant thereof, and a PdB protein and / or a mutant thereof. The vaccine provided by the invention has a protective effect on various streptococcus pneumoniae serotypes.

The invention is directed to an immunogenic composition comprising one or more conjugated bacterial capsular polysaccharides derived from Streptococcus pneumoniae serotypes, a saponin-based adjuvant, and a pharmaceutically acceptable carrier. The invention includes a method of preventing, treating or ameliorating a Streptococcus pneumoniae infection, disease or condition in a subject, comprising administering to the subject an effective amount of an immunogenic composition comprising one or more conjugated bacterial capsular polysaccharides derived from Streptococcus pneumoniae serotypes, a saponin-based adjuvant, and a pharmaceutically acceptable carrier.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.

The present invention relates to novel immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae (glycoconjugates) and uses thereof. The immunogenic compositions of the invention will generally comprise at least one saccharide conjugate from a serotype of Streptococcus pneumoniae that is not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to the use of the novel immunogenic compositions for vaccinating human subjects, particularly infants and the elderly, against pneumococcal infection.